[Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
Fiche publication
Date publication
janvier 2021
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis, Pr RUBIO Marie Thérèse
Tous les auteurs :
Beauvais D, Bachy E, Baruchel A, Bay JO, Caillot D, Cartron G, Damaj G, Furst S, Le Gouill S, Morschhauser F, Rabian F, Rubio MT, Thieblemont C, Yakoub-Agha I
Lien Pubmed
Résumé
The chimeric antigen receptor T-cells are a new class of anticancer treatment consisting in genetically modifying autologous or allogenic T-cells to make express a CAR directed against a membrane tumor antigen. In Europe, tisagenlecleucel (Kymriah) has a marketing authorization for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia in children and young adults and of R/R diffuse large B-cell lymphoma (DLBCL). The marketing authorization for axicabtagene ciloleucel (Yescarta) is the treatment of DLBCL and primary R/R mediastinal B-cell lymphoma. The two products are autologous T-cells directed against CD19. This collaborative work, part of a series of expert opinion-based work, aims to give practical advice to help centers in selection of patients for commercially available CAR T-cell treatment.
Mots clés
B-cell acute lymphoblastic leukemia, CAR T-cells, CD19, Diffuse large B-cell lymphoma, Leucémie aiguë lymphoblastique B, Lymphome diffus à grandes cellules B
Référence
Bull Cancer. 2021 Jan 7;: